Author

B. T. Diamond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:whole-genome sequencing· 3 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

F. Maura· 3 shared G. Morgan· 3 shared K. H. Maclachlan· 3 shared O. Landgren· 3 shared B. Ziccheddu· 2 shared N. Bolli· 2 shared S. Usmani· 2 shared Y. Zhang· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Maura

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Impact of rare structural variant events in newly diagnosed multiple myeloma

M. Chojnacka, B. T. Diamond, B. Ziccheddu, E. Rustad, K. H. Maclachlan, M. Papadimitriou, E. M. Boyle, P. Blaney, S. Usmani, G. Morgan, O. Landgren, F. Maura

This study examines rare structural variants in multiple myeloma patients, showing their association with gene expression changes and potential role in disease pathogenesis.

bioRxiv · Jan 3, 2023 · PreprintCancer Biology

Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms

B. T. Diamond, B. Ziccheddu, K. H. Maclachlan, J. Taylor, E. Boyle, J. Arrango Ossa, J. T. Jahn, M. Affer, T. M. Totiger, D. G. Coffey, J. Watts, S. X. Lu, N. Bolli, K. Bolton, J. H. Park, , F. Maura

The paper reconstructs the evolutionary history of therapy-related myeloid neoplasms using chemotherapy-associated mutational signatures and identifies distinct mutational patterns linked to different chemotherapies.

bioRxiv · Apr 26, 2022 · PreprintCancer Biology

Whole genome sequencing provides evidence of two biologically and clinically distinct entities of asymptomatic monoclonal gammopathies: progressive versus stable myeloma precursor condition

B. Oben, G. Froyen, K. H. Maclachlan, D. Leongamornlert, F. Abascal, B. Zheng-Lin, V. Yellapantula, A. Derkach, E. Geerdens, B. T. Diamond, I. Arijs, B. Maes, K. Vanhees, M. Hultcrantz, E. E. Manasanch, , F. Maura

The paper uses whole genome sequencing to identify two distinct myeloma precursor conditions, progressive and stable, based on genomic features.

bioRxiv · Nov 6, 2020 · PreprintCancer Biology